Kenji Hikita
Direktor/Vorstandsmitglied bei QC Asset, Inc.
Profil
Kenji Hikita is currently a Director at Site Quality Co., Ltd., MediBIC Pharma, MediBIC KK, Animal Stemcell KK, and Ambicion KK.
He is also the Representative Director at QC Asset, Inc. since 2011.
In the past, he worked as a Director & Investor Relations Contact at MediBIC Group from 2013 to 2016.
He graduated from Seikei University in 1988.
Aktive Positionen von Kenji Hikita
Unternehmen | Position | Beginn |
---|---|---|
QC Asset, Inc. | Direktor/Vorstandsmitglied | 01.06.2011 |
MediBIC KK
MediBIC KK Miscellaneous Commercial ServicesCommercial Services Part of MediBIC Group, MediBIC KK develops genomic medicines. The company is based in Tokyo, Japan. The Japanese company was founded by Yasuhiro Hashimoto. | Direktor/Vorstandsmitglied | - |
Animal Stemcell KK
Animal Stemcell KK BiotechnologyHealth Technology Part of MediBIC Group, Animal Stemcell KK engages in research and development, and production of animal stem cells and regenerative medicine. The company is based in Koganei, Japan. Animal Stemcell KK was acquired by MediBIC Group from Resort & Medical Co., Ltd. on October 08, 2013 for $3.02 million. | Direktor/Vorstandsmitglied | - |
Site Quality Co., Ltd.
Site Quality Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Site Quality Co., Ltd. provides consulting services to medical institutions. It offers informed consent acquisition assistance, patient schedule administration, hospital data collection management, time monitoring, case report form preparation support, document creation assistance, and clinical research coordination. The company was founded in November 2003 and is headquartered in Hachioji, Japan. | Direktor/Vorstandsmitglied | - |
MediBIC Pharma | Direktor/Vorstandsmitglied | - |
Ambicion KK
Ambicion KK Miscellaneous Commercial ServicesCommercial Services Ambicion KK is a company based in Tokyo, Japan that focuses on developing novel cancer immunotherapies and allergy treatments. The Japanese company specializes in creating drugs that target NKT cells and promoting cancer immunotherapy that targets NKT cells, which is not covered by insurance. The company was founded in 2015, and the CEO is Kenji Suzuki. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Kenji Hikita
Unternehmen | Position | Ende |
---|---|---|
MEDIBIC GROUP | Direktor/Vorstandsmitglied | 31.05.2016 |
Ausbildung von Kenji Hikita
Seikei University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
MediBIC Group
MediBIC Group Miscellaneous Commercial ServicesCommercial Services MediBIC Group is a holding company which engages in the biotechnology industry that specializes in pharmacogenomics (PGx). It engages in analysis and reporting service on healthcare and drug development; information processing, services and consulting in biotech field; computer system design and development; drug & diagnostic product development; and business consulting services. The firm’s services also include sample banking and management service, GLP-compliant Gene Profiling Service, genetic testing service, licensing, cell culture systems and consumable sale. The company was founded on February 17, 2000 and is headquartered in Tokyo, Japan. | Commercial Services |
Site Quality Co., Ltd.
Site Quality Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Site Quality Co., Ltd. provides consulting services to medical institutions. It offers informed consent acquisition assistance, patient schedule administration, hospital data collection management, time monitoring, case report form preparation support, document creation assistance, and clinical research coordination. The company was founded in November 2003 and is headquartered in Hachioji, Japan. | Commercial Services |
MediBIC Pharma | |
MediBIC KK
MediBIC KK Miscellaneous Commercial ServicesCommercial Services Part of MediBIC Group, MediBIC KK develops genomic medicines. The company is based in Tokyo, Japan. The Japanese company was founded by Yasuhiro Hashimoto. | Commercial Services |
Animal Stemcell KK
Animal Stemcell KK BiotechnologyHealth Technology Part of MediBIC Group, Animal Stemcell KK engages in research and development, and production of animal stem cells and regenerative medicine. The company is based in Koganei, Japan. Animal Stemcell KK was acquired by MediBIC Group from Resort & Medical Co., Ltd. on October 08, 2013 for $3.02 million. | Health Technology |
QC Asset, Inc. | |
Ambicion KK
Ambicion KK Miscellaneous Commercial ServicesCommercial Services Ambicion KK is a company based in Tokyo, Japan that focuses on developing novel cancer immunotherapies and allergy treatments. The Japanese company specializes in creating drugs that target NKT cells and promoting cancer immunotherapy that targets NKT cells, which is not covered by insurance. The company was founded in 2015, and the CEO is Kenji Suzuki. | Commercial Services |